At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
Omarigliptin +1 moredrug
Likely dose
Omarigliptin 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes
In Brief
A Phase 1 clinical trial evaluating Omarigliptin and Placebo for Type 2 Diabetes (T2D). Completed, enrolled 32 participants.
Detailed Summary
This study will test the safety and tolerability of omarigliptin. It is hypothesized that administration of once-weekly omarigliptin in obese but otherwise healthy participants, and in obese participants with Type 2 diabetes (T2D) will be sufficiently safe and well tolerated to permit continued clinical investigation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes (T2D)
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedMar 2010
Primary CompletionMay 2010
TodayJul 2026
First PostedMar 17, 2010
Enrollment StartMar 11, 2010
Primary CompletionMay 11, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.3 years ago
Interventions
Omarigliptindrug
Once-weekly 50 mg capsule
Placebodrug
Once-weekly placebo capsule